DRIVE THERAPEUTICS, L.L.C.

CHAPEL HILL, NC · Biotech · Private

Bispecific aptamers targeting VEGF and IL-8 for retinal disease treatment

drivetherapeutics.com →
Grants
$1.2M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Optimizing Assembly of Bispecific Aptamer Therapeutics$256,000
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Optimizing Manufacturing Efficiency of Bispecific Aptamer Therapeutics$990,477
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1318BOTANISOL, LLC——
1319ONCA BIO, INC.——
1320OASIS PHARMACEUTICALS, LLC——
1321DRIVE THERAPEUTICS, L.L.C.——
1322Morphic Therapeutic——
1323LEFLORE TECHNOLOGIES LLC——
1324NRG Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Bispecific Aptamer Compositions for the Treatment of Retinal Disordersapplication
  • Bispecific Aptamer Compositions For The Treatment Of Retinal Disordersapplication
  • Bispecific Aptamer Compositionsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.